Please login to the form below
opioids
This page shows the latest opioids news and features for those working in and with pharma, biotech and healthcare.
Alkermes slumps as FDA turns down depression drug
The US regulator issued a ‘refusal to file’letter to the company yesterday for the drug, which is a fixed-dose combination of buprenorphine, an opioid used for many years to ... treat addiction, and samidorphan, a new mu-opioid receptor antagonist.
Latest news
-
Mallinckrodt pays $1.2bn for Sucampo Pharma
Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic constipation as well as constipation linked to irritable bowel syndrome and chronic opioid
-
FDA panel backs Indivior’s drug to fight opioid addiction
FDA panel backs Indivior’ s drug to fight opioid addiction. The former RB pharma unit hopes for sales in the $1bn region. ... naloxone), another treatment for opioid dependence, and which raised the threat of low-cost copies reaching the market earlier
-
CHMP backs maintenance therapy for Tesaro's Zejula
Also given the nod were two drugs from Mundipharma intended to help people with opioid addiction – Nyxoid (naloxone) and Zubsolv (buprenorphine/naloxone), while Spanish drugmaker Grifols got the go-ahead for
-
FDA approves first substance use mobile medical application
The trial did not demonstrate the effectiveness of using Reset for opioid abuse and the application is not licensed to treat opioid dependence. ... Reset contains a patient application and clinician dashboard and is indicated as a prescription-only
-
Indivior slumps as patent dispute rises US generic spectre
the treatment of opioid dependence. ... of buprenorphine for treating opioid dependence.
More from news
Approximately 12 fully matching, plus 117 partially matching documents found.
Latest Intelligence
-
Pharma deals continue to slide
Cerecor has sold its kappa opioid receptor antagonist in phase 2 to Janssen (J&J) and Xoma has licensed its interleukin 1 beta intellectual property for cardiovascular disease to Novartis plus ... 74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset
-
Grünenthal's relentless pursuit of relief
It has the potential to reduce pain without typical opioid therapy side effects and is in development for topical application in hypersensitivity disorders such as Bladder Pain Syndrome or Chronic Stump
-
How digital content helps HCPs curb opioid abuse through better prescribing decisions
In fact, a poll of physicians within our digital community found that 64% believe that doctors have a responsibility to help curb opioid abuse. ... And by delivering information concisely and in an engaging format, this approach is having a measurable
-
Deal Watch March 2016
$110. AstraZeneca/ Kyowa Hakko Kirin. Opioid-induced constipation – Moventig. Licence. $70.
-
Pharma deals in September 2015
Zalviso is a combination drug and device product which uses a patient controlled dispenser to deliver a sub-lingual formulation of sufentanil, an opioid with a high therapeutic index.
More from intelligence
Approximately 1 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Egalet appoints Stan Musial as CFO
s pipeline of abuse-deterrent opioids are nearing phase III.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
How digital content is helping physicians curb the opioid abuse epidemic
using their state’ s Prescription Drug Monitoring Program (PDMP) database before prescribing opioids to a patient. ... topic. And there’ s plenty of evidence that this approach works— having a measurable and almost immediate impact on how
-
"Legal highs" ruling leaves illegal labs laughing
So we are acutely aware of the devastation caused by the opioid epidemic in the US, and the criticism aimed at Purdue, the maker of OxyContin. ... We have also pitched for agents designed to treat opioid overdose and alcohol abuse.
-
Research Partnership has published a new Living with Chronic Pain market report for 2016
At least 60% of the patients surveyed are currently prescribed long acting opioids (LAOs).
-
Aptus Health
How digital content is helping physicians curb the opioid abuse epidemic.
More from PMHub
Approximately 1 fully matching, plus 3 partially matching documents found.
Featured jobs
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Group Account Director, Healthcare Brand Communications, London
-
Excellent Package
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Project Manager, Medical Communications, Oxford
-
Excellent Salary
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Account Manager – Med Comms – London
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Scientific Director
-
Great salary and bebefits
-
Senior Programme Executive
-
Salary TBC
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Editor – Medical Education Agency – Bucks
-
Salary TBC
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Medical Writer, e-learning/ training, London
-
Excellent Salary
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Senior Account Director, Healthcare Brand Communications, London
-
Excellent Package
- Project Manager, Medical Communications, London
-
Excellent Salary
-
Senior Medical Writer
-
Great salary and bebefits
Subscribe to our email news alerts
No results were found
- Why heading online for scientific meetings can yield greater HCP engagement
- P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit
- Publicis LifeBrands Team win UK young Cannes Lions competition
- Sobi poaches Pfizer’s Fredrick Wetterlundh
- Rigel and Ultragenyx claim approvals for rare drugs
- VCCP Health strengthens client service team
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...
Latest intelligence
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
- Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
- Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Quick links
Infographics
